Dermatologic drug development involves the creation and testing of new medications specifically designed to treat a wide range of skin conditions, from common issues like acne and eczema to more complex diseases such as psoriasis and skin cancer. The process of developing dermatologic drugs requires a thorough understanding of skin biology, as well as how drugs interact with the skin's layers and systems. Advances in dermatologic drug development have led to targeted therapies, such as biologics and topical immunomodulators, which offer more precise and effective treatments with fewer side effects compared to traditional options. In addition to systemic treatments, innovations in drug delivery systems, such as nanoparticles and liposomes, are improving the effectiveness and penetration of topical treatments. Dermatologic drug development also focuses on personalized medicine, tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors. As research progresses, new therapies continue to emerge, offering better management and potential cures for a range of dermatological diseases.
Irina Sergeeva
Novosibirsk State University, Russian Federation
Dave Ray
Dave Ray Enterprises., United States
George Sulamanidze
Plastic Surgeon at Clinic of Plastic and Aesthetic Surgery and Cosmetology TOTALCharm, Georgia
Sergei A Grando
University of California Irvine, United States
Nino Tsamalaidze
Ltd Karabadini+, Georgia
Lina Petrossian
California University of Science and Medicine, United States
Surajbala Khuraijam
Manipur Health Services, India
Shrutimita Pokhariyal
Symbio, India
Yasser Mohammed Hassanain Elsayed
Egyptian Ministry of Health, Egypt
Title : Paraneoplastic autoimmune multiorgan syndrome or PAMS: Paraneoplastic pemphigus revisited
Sergei A Grando, University of California Irvine, United States
Title : Modern non-invasive methods for in vivo assessment of skin
Georgios N Stamatas, SGS, France
Title : Personalized and precision dermatology through the view of biodesign-inspired translational & data-driven applications: Revolutionary skin treatments for every concern in clinical dermatology integrating skin care experts and consumers
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : The next generation of threads: Lifting, volumization, and biostimulation in one powerful triple action
George Sulamanidze, Plastic Surgeon at Clinic of Plastic and Aesthetic Surgery and Cosmetology TOTALCharm, Georgia
Title : Lymphoproliferative diseases in the practice of a dermatologist
Irina Sergeeva, Novosibirsk State University, Russian Federation
Title : Personalized and precision medicine as a unique avenue to have the healthcare model renewed to secure the national biosafety: Advanced skincare solutions in individualized cosmetology, reconstructive plastic surgery and the modern beauty
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Comparative efficacy of omalizumab and dupilumab in children with Chronic Spontaneous Urticaria (CSU): A retrospective cohort analysis
Molynna Nguyen, University of Toledo, United States
Title : CO2 laser labiaplasty vs. conventional surgical labiaplasty: A comparative clinical approach in outpatient practice
Benosman Sihem, Societe Algerienne De Medecine Esthetique , Algeria
Title : "Mirror mirror on the skin” — A low-cost community strategy to reduce melanoma disparities in Washington, D.C.
Kayla Sampson, Georgetown University School of Medicine, United States
Title : Keratinocyte apoptosis by caspase – 3 Immunostaining in histopathology as marker of activity as well as correlation with dermoscopy findings in Cutaneous Lupus Erythematosus (CLE) in skin of color: An observational study.
Subhojit Ray, All India Institute of Medical Sciences, India